Longwood Fund
Edit

Longwood Fund

https://www.longwoodfund.com
Last activity: 14.02.2025
Active
Longwood creates and invests in science-based companies that develop novel solutions for important medical problems.
Portfolio
1
Mentions
21
Location: United States, Massachusetts, Boston
Employees: 1-10
Founded date: 2010
Investment Type: Venture Capital

Portfolio 1

DateNameWebsiteTotal RaisedLocation
24.06.2022DEM Biopha...dembiopharma.com$70MUnited Sta...

Mentions in press and media 21

DateTitleDescription
15.02.2025Newleos Therapeutics: A New Dawn in Neuropsychiatric TreatmentIn the world of mental health, the need for innovation is as urgent as a fire alarm. Newleos Therapeutics has stepped into this arena with a bold vision and a hefty $93.5 million in Series A funding. This clinical-stage neuroscience company...
14.02.2025Newleos Therapeutics: $93.5 Million (Series A) Raised For Transforming Treatment Of Neuropsychiatric DisordersNewleos Therapeutics—a clinical-stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development—announced the closing of an oversubscribed $93.5 million Series A financing. Goldman Sachs Alternatives led ...
13.02.2025Newleos Therapeutics Debuts with $93.5 Million Oversubscribed Series A Financing to Transform the Treatment of Neuropsychiatric Disorders through the Advancement of Novel Medicines-Newleos aims to develop first-in-class and best-in-class therapies to address the need for safer and more efficacious treatment options for major mental health conditions- -Multiple clinical-stage programs licensed from Roche, ready for pr...
15.01.2025Be Bio Closes $92M Series C FinancingBe Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding. The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management,...
09.11.2024Evommune Secures $115 Million to Tackle Chronic Inflammatory DiseasesIn the bustling world of biotechnology, Evommune has made waves. The Palo Alto-based company recently secured $115 million in Series C financing. This funding is a lifeline, aimed at advancing their clinical-stage pipeline focused on immune...
08.11.2024Evommune: $115 Million (Series C) Secured To Advance Clinical-Stage Pipeline Addressing Chronic Inflammatory DiseasesEvommune – a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases – announced the completion of a $115 million Series C financing. The funding was co-led by new investors RA...
28.10.2024Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New FundingIn the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn...
25.10.2024Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell MedicinesBe Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo...
03.04.2024From generative chemistry to computational astrophysics, startups employ new methods to fight cancerHere are a few startups in the cancer space that made headlines recently The recent revelation of Princess Kate Middleton’s battle with cancer has sent ripples across the globe, reminding us that this disease knows no boundaries of status o...
19.03.2024Engrail Therapeutics raises $157M Series BEngrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced that it has closed an oversubscribed $157 million Series B financing round. Th...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In